Twist Bioscience (TWST) and Element Biosciences announced an expanded collaboration to enable Element’s AVITI systems and Trinity flowcells with additional Twist library preparation and target enrichment workflows. Twist will be the exclusive partner for these new workflows compatible with Element’s Trinity sequencing technology. The companies will also engage in joint commercial and promotional activities to expand customer access to these next-generation sequencing tools.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Here’s Why Cathie Wood Walked Away from PLTR and ACHR Stocks
- Twist Bioscience, Ginkgo Bioworks revise collaboration agreement
- Cathie Wood’s ARK Investment buys 283.2K shares of Twist Bioscience today
- Twist Bioscience price target lowered to $44 from $54 at Baird
- Cautious Outlook on Twist Bioscience Amidst Macroeconomic Challenges and Premium Valuation